These findings suggest that targeting oxidative stress via these molecular pathways like MAPK, TLR4/NF-κB, Nrf2, and PI3K/Akt may offer new therapeutic strategies for managing IBD. The gene discussed is NFE2L2; the disease is irritable bowel syndrome.